GlassScriptPhysician profile
Fahad Alam
NPI 1518457894
$1,168.54
in general payments reported to CMS, 2019-2025
27 companies · $379 in 2025
The $379 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $107 · 2021: $76.98 · 2022: $323 · 2023: $161 · 2024: $122 · 2025: $379.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $662.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $661.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $161.49 | 2022-2025 | Wegovy, Rybelsus, Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $143.44 | 2022-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $141.84 | 2021-2025 | |
| Actelion Pharmaceuticals US, INC. | $77.45 | 2025 | Opsumit, Uptravi |
| Abbvie INC. | $53.95 | 2021-2024 | Qulipta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $49.09 | 2022-2023 | Xifaxan |
| Astellas Pharma US INC | $48.23 | 2023 | Veozah, Myrbetriq |
| Amgen INC. | $32.56 | 2021-2022 | |
| Boston Scientific Corporation | $27.78 | 2022-2025 | Watchman Access System |
| E.R. Squibb & Sons, L.L.C. | $27.71 | 2022-2025 | Eliquis |
| Alexion Pharmaceuticals, INC. | $25.96 | 2024 | Strensiq |
| Antares Pharma, INC. | $23.66 | 2022 | |
| Xeris Pharmaceuticals, INC. | $22.47 | 2023 | Gvoke Hypopen |
| Pfizer INC. | $22.41 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $18.57 | 2025 | Airsupra |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $18.14 | 2025 | |
| Glaxosmithkline, LLC. | $17.62 | 2023 | Arexvy, Shingrix |
| Otsuka America Pharmaceutical, INC. | $17.31 | 2025 | Rexulti |
| Ultragenyx Pharmaceutical INC. | $17.30 | 2021 | |
| Lilly USA, LLC | $16.84 | 2022 | |
| Janssen Pharmaceuticals, INC | $15.88 | 2022 | |
| Ascensia Diabetes Care US INC. | $15.59 | 2024 | |
| Sumitomo Pharma America, INC. | $14.82 | 2023 | Gemtesa |
| Exact Sciences Corporation | $14.62 | 2025 | Cologuard Collection Kit |
| Arbor Pharmaceuticals, INC. | $14.45 | 2021 | |
| Dexcom, INC. | $12.61 | 2022 | |
| Abbott Laboratories | $10.11 | 2024 | Freestyle Libre 3 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fahad Alam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.